EVALUATION OF THE PROGRESS REPORT

Date: March 7, 2025.
Details: The Research and Innovation Foundation completed the interim scientific and financial evaluation, rated the project as "Very Good," and approved the second funding instalment.

PRESENTATION OF THE INTERIM SCIENTIFIC REPORT

Date: December 16, 2024.
Details: The project coordinator presented the interim scientific report to the Research and Innovation Foundation officer

INTERIM OF THE PROJECT

Date: December 11, 2024.
Details: Submission of scientific and financial interim reports. Key activities included:

1. Synthesis Trials: Nitroso-Amisulpride synthesis halted; replaced by Nitroso-Adrenaline.
2. Analytical Trials: Purity determination and structure identification of six nitroso impurities.
3. Ongoing Work: Synthesis and purification of Liraglutide impurities.

APPROVAL OF THE AMENDMENT

Date: August 30, 2024.
Details: Approval of project amendment by the Research and Innovation Foundation.

AMENDMENT OF THE PROJECT

Date: July 31, 2024.
Details: Requested changes included:

1. Extension of WP3 completion to the 17th month.
2. Adjustment of WP3 deliverables timeline.
3. Early commencement of WP4.
4. Replacement of Nitroso-Amisulpride with Nitroso-Adrenaline.

INITIATION OF THE PROJECT

The duration of the project is 24 months. Implementation Start Date is set from December 1, 2023, and Project Completion Date is set from November 30, 2025.

PROJECT OBJECTIVES

Goals: Synthesize six nitrosamine impurities and three Liraglutide impurities, determine their purity, and develop detection methods.
Commercialization: Promote products domestically and internationally, leveraging BRI's partner network.

SIGNING PROJECT

Date: October 23, 2023.
Details: The project contract was signed between the Research and Innovation Foundation and Biopharm Research Institute Ltd. The project, identified by Protocol No. ENTERPRISES/0223/Sub-Call1/0056 and titled “Nitroso and Peptide Impurities” (acronym ‘NPI’), was selected under the RESTART “RESEARCH IN ENTERPRISES 2023” Programme, Pillar I - Smart Growth. The requested funding from RIF can be up to €178,516.80.

‘The Project is funded by the European Union Recovery and Resilience Facility of the NextGenerationEU instrument, through the Research and Innovation Foundation.’

Biopharm Research Institute LTD has earned within the contexts of the operational program «Θ.Αλ.Ε.Ι.Α» 2021-2027 a public funding for the implementation of it. Through this program, the company will invest in the purchase of new laboratory equipment (HPLC, laboratory fridges, Microwave Peptide Synthesizer, Air Purifier and Freeze Dryer).

‘The Project is funded by the European Union through the Ministry of Energy, Commerce and Industry’